Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT00131014
Collaborator
(none)
1,500
1
220.7
6.8

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate possible genetic factors that contribute to the development of lymphomas. The databank will be used to determine whether familial lymphomas have unique genetic characteristics different from sporadic lymphomas and to attempt to identify a gene that confers an increased risk of lymphoma.

Detailed Description

  • Patients who participate will be asked to complete detailed family and medical history questionnaires initially, with a follow-up questionnaire every year.

  • Patients will be asked to supply a blood sample and possibly a mouthwash sample, both of which can be done by mail.

  • Patients will be asked to consent to the release of their lymphoma tissue block for the purposes of the study.

  • Patients will be given letters of invitation for their affected relatives to invite them to participate.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1500 participants
Observational Model:
Family-Based
Time Perspective:
Prospective
Official Title:
Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies
Actual Study Start Date :
Aug 9, 2004
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Next of Kin of deceased subj by lymphoma

Next of Kin of deceased subject by lymphoma

Subject unaffected by lymphoma

Subject unaffected by lymphoma

Subject affected by lymphoma

Subject affected by lymphoma

Outcome Measures

Primary Outcome Measures

  1. Genetic factors that contribute to the development of lymphomas and CLL [Indefinite]

    Genetic factors that contribute to the development of lymphomas and CLL

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.

  • Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.

  • Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.

  • Age > 18 years

Exclusion Criteria:
  • Subjects without a family history of lymphoma

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dana-Farber Cancer Institute Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Dana-Farber Cancer Institute

Investigators

  • Principal Investigator: Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jennifer R. Brown, MD, PhD, Assistant Professor of Medicine, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00131014
Other Study ID Numbers:
  • 04-165
First Posted:
Aug 17, 2005
Last Update Posted:
Aug 2, 2022
Last Verified:
Aug 1, 2022
Keywords provided by Jennifer R. Brown, MD, PhD, Assistant Professor of Medicine, Dana-Farber Cancer Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2022